Tags

Type your tag names separated by a space and hit enter

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
Am J Ophthalmol 2009; 148(6):875-82.e1AJ

Abstract

PURPOSE

To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration.

DESIGN

Prospective, double-masked, randomized clinical trial.

METHODS

This is a single-center, randomized clinical trial at the Boston Veterans Affairs Healthcare System. Patients who met inclusion criteria were randomized 2:1 to bevacizumab or ranibizumab. Each patient contributed 1 eye to the study. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity (VA) was checked on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by optical coherence tomography-guided, variable-dosing schedule. Main outcomes measured were VA and foveal thickness.

RESULTS

Twenty patients completed the 6-month follow up. Thirteen patients received bevacizumab and 7 patients received ranibizumab. No subjects in either group lost more than 15 letters on ETDRS chart. The average preoperative VA was 31.6 letters in the bevacizumab group and 30.4 letters in the ranibizumab group. At 6 months follow-up, mean vision was 46.4 letters in the bevacizumab group and 37.4 letters in the ranibizumab group. Two-tailed ttest failed to show statistical significance between the two groups. Patients in the bevacizumab group underwent an average of 5 injections, while patients in the ranibizumab group underwent a mean of 4 injections.

CONCLUSION

Early results of a head-to-head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of age-related macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance.

Authors+Show Affiliations

Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts, USA. manju.subramanian@bmc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

19800611

Citation

Subramanian, Manju L., et al. "Bevacizumab Vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-masked, Randomized Clinical Trial." American Journal of Ophthalmology, vol. 148, no. 6, 2009, pp. 875-82.e1.
Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol. 2009;148(6):875-82.e1.
Subramanian, M. L., Ness, S., Abedi, G., Ahmed, E., Daly, M., Feinberg, E., ... Houranieh, A. (2009). Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. American Journal of Ophthalmology, 148(6), pp. 875-82.e1. doi:10.1016/j.ajo.2009.07.009.
Subramanian ML, et al. Bevacizumab Vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-masked, Randomized Clinical Trial. Am J Ophthalmol. 2009;148(6):875-82.e1. PubMed PMID: 19800611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. AU - Subramanian,Manju L, AU - Ness,Steven, AU - Abedi,Gelareh, AU - Ahmed,Ednan, AU - Daly,Mary, AU - Feinberg,Edward, AU - Bhatia,Sumit, AU - Patel,Payal, AU - Nguyen,Maileah, AU - Houranieh,Antoun, Y1 - 2009/10/02/ PY - 2009/02/23/received PY - 2009/06/24/revised PY - 2009/07/13/accepted PY - 2009/10/6/entrez PY - 2009/10/6/pubmed PY - 2009/12/16/medline SP - 875 EP - 82.e1 JF - American journal of ophthalmology JO - Am. J. Ophthalmol. VL - 148 IS - 6 N2 - PURPOSE: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration. DESIGN: Prospective, double-masked, randomized clinical trial. METHODS: This is a single-center, randomized clinical trial at the Boston Veterans Affairs Healthcare System. Patients who met inclusion criteria were randomized 2:1 to bevacizumab or ranibizumab. Each patient contributed 1 eye to the study. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity (VA) was checked on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by optical coherence tomography-guided, variable-dosing schedule. Main outcomes measured were VA and foveal thickness. RESULTS: Twenty patients completed the 6-month follow up. Thirteen patients received bevacizumab and 7 patients received ranibizumab. No subjects in either group lost more than 15 letters on ETDRS chart. The average preoperative VA was 31.6 letters in the bevacizumab group and 30.4 letters in the ranibizumab group. At 6 months follow-up, mean vision was 46.4 letters in the bevacizumab group and 37.4 letters in the ranibizumab group. Two-tailed ttest failed to show statistical significance between the two groups. Patients in the bevacizumab group underwent an average of 5 injections, while patients in the ranibizumab group underwent a mean of 4 injections. CONCLUSION: Early results of a head-to-head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of age-related macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance. SN - 1879-1891 UR - https://www.unboundmedicine.com/medline/citation/19800611/Bevacizumab_vs_ranibizumab_for_age_related_macular_degeneration:_early_results_of_a_prospective_double_masked_randomized_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(09)00505-4 DB - PRIME DP - Unbound Medicine ER -